Study
FGF
Follow-up, weeks
Patients FGF/PB
Male, % FGF/PB
Age, y FGF/PB
BMI ‡, FGF/PB
Fibrosis stage III/IV, % FGF/PB
ALT, U/liter FGF/PB
TG, mg/ml FGF/PB
HbA1c,% FGF/PB
BALANCED 2021 Efruxifermin 30 59/21 47.5/28.5 52.0/52.4 37.5/37.6 28.8/38 57.4/50.7 177.7/208.3 6.28/6.49
HARMONY 2023 Efruxifermin 96 85/43 38.8/37.2 54.4/ 55 37.7/38.7 63.5/69.7 56.5/62.2 156.1/ 169.7 6.7/ 6.8
ENLIVEN 2023 Pegozafermin 46 151/71 36.4/32 55.2/56.3 35.8/38.1 64.9/69.1 58.7/49.6 172.6/170.3 6.6/6.6
FALCON 1 2024 Pegbelfermin 48 148/49 41,2/40,8 56.6/57.5 35.6/35.2 100 53.4/53.4 163.8/ 200.4 6.8/6.9
FALCON 2 2024 Pegbelfermin 121 115/39 35.6/38.4 58.6/61.4 35.6/35.4 100 48.7/48.3 154.0/133.4 6.9/7.0
Sanyal 2018 Pegbelfermin 16 49/26 34.6/38.4 52/47 34.4/37 7/1 67.9/80 198.2/ 171 6.1/6.0
Loomba 2023 Pegozafermin 53 62/19 38.7/36.8 51.7/52.6 34.8/33.8 NA 42.2/38.8 NA NA
BALANCED Cohort C 2023 Efruxifermin 16 20/10 20/70 57.1/61.1 36.0/39.1 NA 31.7/32.7 134.6/121.7 6.1/ 6.6